STOCKHOLM, Sweden, 22 February 2023 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January – December 2022. The report is available on the company's website lipidor.se and in the attached pdf. Summary of year-end report During the period, the company conducted a Phase III study, […]
Lipidor AB (publ) (“Lipidor” or the “Company”) held an extraordinary general meeting (the “EGM”) on 17 January 2023 in Stockholm. The EGM resolved to approve that the Company transfer shares in the subsidiary Emollivet AB to two major shareholders in Lipidor. Transfer of shares in the subsidiary Emollivet The EGM resolved, in accordance with the […]
The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (“Lipidor” or the “Company”) are hereby given notice to attend the Extraordinary General Meeting (the “EGM”) on 17 January 2023 at 13.00 CET at Fredersen Advokatbyrå’s premises, Lästmakargatan 18 in Stockholm. Registration starts at 12.30 CET. NOTE: This is an unofficial translation of the original Swedish […]
STOCKHOLM, 23 December 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI), (“Lipidor” or the “Company”) today announces that the Board has resolved to summon an Extraordinary General Meeting (“EGM”) for approval of the sale of parts of Lipidor’s shareholding in the subsidiary Emollivet AB (“Emollivet”) to two of Lipidor’s major shareholders. Notice […]
STOCKHOLM, Sweden, 14th December 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI), (“Lipidor” or the “Company”) today announces that the Company has secured a bridge financing of at least SEK 5 million. The bridge financing provides extended endurance and the financial space to complete, together with the Company's licensing partner RELIFE S.r.l., […]
STOCKHOLM, Sweden, 8 December 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall have four members, in accordance with the applicable instructions resolved by the Annual General Meeting 2020. The three largest shareholders who are registered with Euroclear Sweden AB on the last of September before […]
STOCKHOLM, Sweden, 23 November 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – September 2022. The report is available on the company's website lipidor.se and in the attached pdf. Summary of interim report During the period, the company conducted a Phase III study […]
STOCKHOLM, 15 November 2022 – On October 28, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced that the Phase III study with the combination preparation AKP02 did not achieve the criterion of equivalent therapeutic efficacy in the treatment of psoriasis compared to the market-leading reference product. However, the study results show that AKP02 […]
STOCKHOLM 28 October 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study did not achieve the study's primary goal of achieving non-inferiority of therapeutic efficacy in the treatment of psoriasis compared to the reference product. However, AKP02 shows clearly better efficacy than placebo. The study […]
GOTHENBURG, Sweden, 7th October 2022 – Earlier this year, Lipidor’s subsidiary Emollivet launched Emollivet COMBI – an antiseptic emollient spray for horses with pastern dermatitis. The product has generated great interest among horse owners, and recently the milestone of 1,000 products sold was reached. The company is now preparing for scaled-up production to meet the […]